M1A.2790 Drug-induced chronic gout, unspecified ankle and foot, without tophus (tophi)

Name of the Condition

• Drug-Induced Chronic Gout, Unspecified Ankle and Foot, Without Tophus (Tophi)

Summary

Drug-induced chronic gout, unspecified ankle and foot, without tophus is a form of arthritis affecting the ankle and foot joints, resulting from prolonged elevated uric acid levels due to medication use. It leads to recurrent joint inflammation and potential tissue damage, characterized by persistent symptoms without the presence of tophi (urate crystal deposits) in this stage.

Causes

This condition arises from medications that interfere with uric acid metabolism or excretion, causing accumulation in the blood. Over time, urate crystals deposit in the ankle and foot joints and surrounding tissues, triggering inflammation. Common culprits include diuretics, low-dose aspirin, and certain chemotherapy agents.

Risk Factors

• Use of medications that increase uric acid levels (e.g., diuretics, low-dose aspirin)
• Prolonged exposure to urate-raising drugs
• Pre-existing hyperuricemia or gout history
• Renal impairment affecting drug clearance

Symptoms

• Recurrent episodes of intense ankle or foot pain, often with swelling and redness
• Persistent warmth and tenderness in the affected joints
• Stiffness and limited range of motion in the affected joints
• Flare-ups triggered by stress, diet, or illness

Diagnosis

Diagnosis involves a combination of clinical evaluation, patient history (including medication use), and laboratory tests to measure uric acid levels. Joint fluid analysis may be performed to detect urate crystals, and imaging studies (e.g., X-rays) can assess joint damage. The absence of tophi is confirmed during physical examination and imaging.

Treatment Options

Treatment focuses on managing uric acid levels and reducing inflammation. This may include discontinuing or adjusting the causative medication, prescribing urate-lowering therapy (e.g., allopurinol), and using anti-inflammatory drugs (e.g., NSAIDs or colchicine) to control acute flare-ups. Lifestyle modifications, such as dietary changes, may also be recommended.

Prognosis and Follow-Up

With appropriate management, symptoms can be controlled, and joint damage may be minimized. Regular follow-up is necessary to monitor uric acid levels, adjust medications, and assess for progression. Early intervention improves outcomes and reduces the risk of complications.

Complications

Untreated or poorly managed cases may lead to chronic joint damage, persistent pain, and reduced mobility. While tophi are not present in this stage, progression to tophaceous gout or kidney stones (nephrolithiasis) can occur if uric acid levels remain elevated.

Lifestyle & Prevention

• Avoid or limit medications known to raise uric acid levels, when possible.
• Maintain a balanced diet low in purines (e.g., limit red meat, seafood, and alcohol).
• Stay hydrated to support uric acid excretion.
• Follow prescribed treatment plans consistently to control uric acid levels.

When to Seek Professional Help

Seek medical attention if experiencing severe or worsening joint pain, swelling, or redness in the ankle or foot, or if symptoms do not improve with initial treatment. Prompt evaluation is important to prevent long-term joint damage.

Tips for Medical Coders

This code (M1A.2790) specifies drug-induced chronic gout affecting the unspecified ankle and foot without tophus. Documentation should clearly indicate the absence of tophi and the involvement of the ankle/foot region. Ensure the causative medication and chronic nature of the condition are supported by clinical notes.